Literature DB >> 2775613

Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver.

F Broly1, C Libersa, M Lhermitte, P Bechtel, B Dupuis.   

Abstract

1. The kinetics of dextromethorphan O-demethylation were measured in microsomes prepared from five human livers, both in the absence and in the presence of quinidine. 2. For each liver and over the concentration range of dextromethorphan examined (4.2-3400 microM), this reaction involved an enzymatic component of high affinity, with an apparent Michaelis-Menten constant (Km) of 4.6 +/- 1.8 microM (mean +/- s.d.) and a maximum velocity (Vmax) of 4.2 +/- 3.5 nmol mg-1 h-1 (mean +/- s.d.). 3. Quinidine was a potent and competitive inhibitor of the activity of this component (mean Ki +/- s.d. of 0.025 +/- 0.008 microM) as it is for other oxidation reactions which have already been found to co-segregate with the debrisoquine-type polymorphism. 4. With microsomes from four of the five livers studied, there was evidence of a second enzymatic component of activity characterized by a similar Vmax and about 20-fold higher Km compared with the high affinity component. The activity of this low affinity component was unaffected by quinidine in the concentrations studied.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2775613      PMCID: PMC1379967          DOI: 10.1111/j.1365-2125.1989.tb03502.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  35 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.

Authors:  A Küpfer; B Schmid; R Preisig; G Pfaff
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

3.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

Authors:  S V Otton; T Inaba; W Kalow
Journal:  Life Sci       Date:  1984-01-02       Impact factor: 5.037

Review 4.  Inherited defects of hepatic drug metabolism.

Authors:  A Küpfer; R Preisig
Journal:  Semin Liver Dis       Date:  1983-11       Impact factor: 6.115

5.  Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.

Authors:  P J Meier; H K Mueller; B Dick; U A Meyer
Journal:  Gastroenterology       Date:  1983-09       Impact factor: 22.682

Review 6.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.

Authors:  D S Davies; G C Kahn; S Murray; M J Brodie; A R Boobis
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

8.  Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes.

Authors:  C von Bahr; E Spina; C Birgersson; O Ericsson; M Göransson; T Henthorn; F Sjöqvist
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

9.  Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.

Authors:  L M Distlerath; P E Reilly; M V Martin; G G Davis; G R Wilkinson; F P Guengerich
Journal:  J Biol Chem       Date:  1985-07-25       Impact factor: 5.157

10.  Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography.

Authors:  Y H Park; M P Kullberg; O N Hinsvark
Journal:  J Pharm Sci       Date:  1984-01       Impact factor: 3.534

View more
  17 in total

1.  Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.

Authors:  Z Desta; N V Soukhova; D A Flockhart
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.

Authors:  J G Shin; K Kane; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

3.  Pharmacological profile of non-hydroxylated and ether derivatives of the potent D2-selective agonist N-0437.

Authors:  J M Jansen; I den Daas; H Rollema; P J Swart; P G Tepper; J B de Vries; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-02       Impact factor: 3.000

4.  Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.

Authors:  Ji-Hong Shon; Young-Ran Yoon; Min-Jung Kim; Kyoung-Ah Kim; Young-Chae Lim; Kwang-Hyeon Liu; Dong-Hoon Shin; Chung Han Lee; In-June Cha; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

5.  The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine.

Authors:  Sally Usdin Yasuda; Peter Zannikos; Andrea E Young; Karen M Fried; Irving W Wainer; Raymond L Woosley
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

6.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Authors:  A A Moghadamnia; A Rostami-Hodjegan; R Abdul-Manap; C E Wright; A H Morice; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

7.  Dextromethorphan O-demethylation polymorphism in Jordanians.

Authors:  Y M Irshaid; H F al-Hadidi; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

Authors:  F Broly; N Vandamme; C Libersa; M Lhermitte
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

9.  Involvement of CYP1A2 in mexiletine metabolism.

Authors:  M Nakajima; K Kobayashi; N Shimada; S Tokudome; T Yamamoto; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

10.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

Authors:  R F Tyndale; W Kalow; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.